IP Library › Granted Patent US 9,989,524
Granted Patent B2
US 9,989,524 · App. 14/173,656 · Granted Jun 5, 2018

Immuno imaging agent for use with antibody-drug conjugate therapy

Inventors: Jochen Kruip (Erzhausen, DE); Susanta K. Sarkar (Cambridge, MA); Mathias Gebauer (Frankfurt, DE); Christian Lange (Frankfurt, DE); Ingo Focken (Hocheim, DE)
Assignee: SANOFI
G01N33/5308A61K47/48384A61K47/48561A61K47/48569A61K51/1027A61K51/1045C07K16/3092A61K2039/505C07K2317/24C07K2317/55C07K2317/56C07K2317/626C07K2317/64C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,989,524
App. No.
14/173,656
Granted
Jun 5, 2018
Kind
B2
Abstract

The invention relates to a companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody, DS6, to be used as diagnostic tool for in vivo detection and quantification of the tumor-associated MUC1-sialoglycotope, CA6.

Claims (44)

1. An antibody-like binding protein that specifically binds CA6, wherein the antibody-like binding protein comprises two polypeptides having structures represented by the formulas [I] and [II] below:

V L1 -L 1 -V L2 -C L   [I]

V H1 -L 2 -V H2 -C H1   [II]

wherein:

V L1 is an immunoglobulin light chain variable domain comprising SEQ ID NO: 2;

V L2 is an immunoglobulin light chain variable domain comprising SEQ ID NO: 2;

V H1 is an immunoglobulin heavy chain variable domain comprising SEQ ID NO: 8;

V H2 is an immunoglobulin heavy chain variable domain comprising SEQ ID NO: 8;

C L is an immunoglobulin light chain constant domain;

C H1 is an immunoglobulin C H1 heavy chain constant domain;

L 1 and L 2 are amino acid linkers; and

wherein the polypeptides of formula I and the polypeptides of formula II form a bivalent monospecific tandem immunoglobulin antibody-like binding protein.

2. The antibody-like binding protein of claim 1 , wherein L 1 is GGGGS (SEQ ID NO: 15) or GGGGSGGGGS (SEQ ID NO: 3).

3. The antibody-like binding protein of claim 1 , wherein L 2 is GGGGS (SEQ ID NO: 15) or GGGGSGGGGS (SEQ ID NO: 3).

4. The antibody-like binding protein of claim 1 , wherein L 1 and L 2 are identical.

5. The antibody-like binding protein of claim 1 , wherein V L1 and V L2 domains are identical.

6. The antibody-like binding protein of claim 1 , wherein V H1 and V H2 are identical.

7. The antibody-like binding protein of claim 1 , wherein the polypeptide of formula [I] comprises SEQ ID NO: 1.

8. The antibody-like binding protein of claim 1 , wherein the polypeptide of formula [II] comprises SEQ ID NO: 7.

9. The antibody-like binding protein of claim 1 , further comprising a tag.

10. The antibody-like binding protein of claim 9 , wherein the tag is 6x-Histidine, biotin, MYC, V5, FLAG, MBP, or glutathione-S-transferase, or HA.

11. The antibody-like binding protein of claim 10 , wherein the tag is a 6x-Histidine tag.

12. The antibody-like binding protein of claim 1 , further comprising at least one radiolabel, imaging agent, therapeutic agent, or diagnostic agent.

13. The antibody-like binding protein of claim 12 , wherein the radiolabel, imaging agent, therapeutic agent, or diagnostic agent is 110 In, 111 In, 177 Lu, 18 F, 52 Fe, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 86 Y, 90 Y, 89 Zr, 94 Tc, 94 Tc, 99m Tc, 120 I, 123 I, 124 I, 125 I, 131 I, 154-158 Gd, 32 P, 11 C, 13 N, 15 O, 186 Re, 188 Re, 51 Mn, 52m Mn, 55 Co, 72 As, 75 Br, 76 Br, 82m Rb, 83 Sr.

14. The antibody-like binding protein of claim 12 , wherein the radiolabel, imaging agent, therapeutic agent, or diagnostic agent comprises one or more agents for magnetic resonance imaging (MRI); positron emission tomography (PET); single photon emission tomography (SPECT); optical imaging, computed tomography (CT); ultrasound, X-ray, or photoacoustic imaging.

15. A method for making an antibody-like binding protein that specifically binds CA6, comprising expressing in a cell one or more nucleic acid molecules encoding polypeptides having structures represented by the formulas [I] and [II] below:

V L1 -L 1 -V L2 -C L   [I]

V H1 -L 2 -V H2 -C H1   [II]

wherein:

V L1 is an immunoglobulin light chain variable domain comprising SEQ ID NO: 2;

V L2 is an immunoglobulin light chain variable domain comprising SEQ ID NO: 2;

V H1 is an immunoglobulin heavy chain variable domain comprising SEQ ID NO: 8;

V H2 is an immunoglobulin heavy chain variable domain comprising SEQ ID NO: 8;

C L is an immunoglobulin light chain constant domain;

C H1 is an immunoglobulin C H1 heavy chain constant domain;

L 1 and L 2 are amino acid linkers; and

wherein the polypeptides of formula I and the polypeptides of formula II form a bivalent monospecific tandem immunoglobulin antibody-like binding protein.

16. The method of claim 15 , wherein said antibody-like binding protein is an antibody-like binding protein further comprises a tag.

17. The method of claim 16 , wherein the tag is 6x-Histidine, biotin, MYC, V5, FLAG, MBP, glutathione-S-transferase, or HA.

18. The method of claim 17 , wherein the tag is a 6x-Histidine tag.

19. The antibody-like binding protein of claim 1 , wherein C L is a human IGKC immunoglobulin light chain constant domain.

20. The antibody-like binding protein of claim 1 , wherein C H1 is a human immunoglobulin C H1 heavy chain constant domain.

21. The antibody-like binding protein of claim 15 , wherein C L is a human IGKC immunoglobulin light chain constant domain.

22. The antibody-like binding protein of claim 15 , wherein C H1 is a human immunoglobulin C H1 heavy chain constant domain.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2017
From: KRUIP, JOCHEN; SARKAR, SUSANTA; GEBAUER, MATHIAS; LANGE, CHRISTIAN; FOCKEN, INGO
To: SANOFI
Reel/Frame 043797/0980 →
Continuity (2)
Provisional Application 61761190 · Feb 5, 2013
Related Publication 20140256916A1 · Sep 11, 2014